Automate Your Wheel Strategy on DHR
With Tiblio's Option Bot, you can configure your own wheel strategy including DHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DHR
- Rev/Share 33.5143
- Book/Share 73.0523
- PB 2.8622
- Debt/Equity 0.3545
- CurrentRatio 1.6194
- ROIC 0.0567
- MktCap 149697745405.0
- FreeCF/Share 6.7858
- PFCF 30.7893
- PE 43.8885
- Debt/Assets 0.2273
- DivYield 0.0059
- ROE 0.0669
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | DHR | Rothschild & Co Redburn | Buy | Neutral | -- | $220 | Oct. 8, 2025 |
| Upgrade | DHR | Scotiabank | Sector Perform | Sector Outperform | -- | $275 | July 11, 2025 |
| Upgrade | DHR | Barclays | Equal Weight | Overweight | -- | $205 | April 10, 2025 |
| Upgrade | DHR | Goldman | Neutral | Buy | -- | $260 | March 21, 2025 |
| Upgrade | DHR | Stifel | Hold | Buy | -- | $260 | March 14, 2025 |
| Downgrade | DHR | Raymond James | Outperform | Market Perform | -- | -- | Feb. 3, 2025 |
| Initiation | DHR | Scotiabank | -- | Sector Perform | -- | -- | Dec. 23, 2024 |
| Initiation | DHR | Guggenheim | -- | Buy | -- | $275 | Dec. 19, 2024 |
| Upgrade | DHR | BofA Securities | Neutral | Buy | -- | $290 | Dec. 13, 2024 |
| Initiation | DHR | Stephens | -- | Overweight | -- | $315 | Oct. 1, 2024 |
News
Danaher (DHR) Q3 Earnings and Revenues Beat Estimates
Published: October 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Danaher (DHR) came out with quarterly earnings of $1.89 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.71 per share a year ago.
Read More
Danaher beats quarterly estimates on strength in diagnostic tools and tech
Published: October 21, 2025 by: Reuters
Sentiment: Positive
Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3% in premarket trading.
Read More
Danaher Reports Third Quarter 2025 Results
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89.
Read More
LH vs. DHR: Which Stock Is the Better Value Option?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR gears up for Q3 results with steady earnings estimates and mixed segment trends across Life Sciences, Biotechnology and Diagnostics.
Read More
Wall Street's Insights Into Key Metrics Ahead of Danaher (DHR) Q3 Earnings
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Danaher Stock: Monopoly Margins, Discounted Price
Published: October 15, 2025 by: Forbes
Sentiment: Positive
Danaher (NYSE:DHR) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Read More
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=17717 for more information.
Read More
Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
Read More
Danaher's Life Sciences Segment Shrinks: What's the Path Forward?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.
Read More
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
DHR's Biotechnology unit grows 6% in Q2, driven by bioprocessing, despite weakness in research equipment demand.
Read More
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
Published: September 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
Read More
Danaher Gains From Business Strength Amid Persisting Headwinds
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.
Read More
Danaher (DHR) Up 6.8% Since Last Earnings Report: Can It Continue?
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Read More
Danaher (DHR) Just Overtook the 200-Day Moving Average
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Danaher (DHR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DHR broke through the 200-day moving average, which suggests a long-term bullish trend.
Read More
CVS or DHR: Which Is the Better Value Stock Right Now?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
International Markets and Danaher (DHR): A Deep Dive for Investors
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Danaher Q2 2025 Update
Published: July 24, 2025 by: Seeking Alpha
Sentiment: Negative
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.
Read More
CVS or DHR: Which Is the Better Value Stock Right Now?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Read More
Here's Why Danaher (DHR) is a Strong Growth Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Danaher Stock: Attractively Valued And Poised For Growth Acceleration
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Positive
Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.
Read More
Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Neutral
Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.
Read More
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Read More
Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Read More
45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' dividend dogs, with prices below annual dividends from $1,000 invested, signaling attractive entry points. The top ten high-yield picks offer projected 24.3% average net gains by July 2026, with lower-than-market volatility, but some face negative free cash flow margins.
Read More
CVS vs. DHR: Which Stock Is the Better Value Option?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Danaher (DHR) is a Top Growth Stock for the Long-Term
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Danaher: High Capex And Low Debt Despite Trump Legislation
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Positive
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
Read More
About Danaher Corporation (DHR)
- IPO Date 1978-12-29
- Website https://www.danaher.com
- Industry Medical - Diagnostics & Research
- CEO Rainer M. Blair
- Employees 61000